Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Nepstar Prices IPO at 30% Premium to Range

publication date: Nov 9, 2007
Remember market conditions? The blanket excuse that is trotted out whenever any company fails to find investors in an IPO? Well, market conditions are a little dicey at the moment, but China Nepstar  nevertheless managed to price its IPO at $16.20, which was 30% above the proposed range of $11.50 to $13.50. Prospects trump market conditions, again. In very early open market trading, China Nepstar moved another $2.80 higher to $19 per share. More details...

Stock sybmol: (NYSE: NPD)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital